EMERALD-3
In 2026 a dual-immunotherapy regimen plus lenvatinib added to TACE cut the risk of progression by about 30%; whether it extends life is not yet known.
Met its primary PFS endpoint (HR ~0.70) at interim analysis, presented ASCO 2026; OS trended favourably but was not formally tested. Third positive-for-PFS TACE combination trial after EMERALD-1 and LEAP-012.
- The treated group had about 30 percent lower chance of the event at any given time (hazard ratio 0.7).
- The absolute difference, how many more people out of 100 were helped, is not reported here.
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: Embolisation-eligible unresectable HCC: STRIDE (durvalumab + tremelimumab) + lenvatinib + TACE vs TACE. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Pages like this
not linked directly; found by shared links- TrialEMERALD-1
Shares TACE + immunotherapy/anti-VEGF, Transarterial chemoembolisation (TACE), Durvalumab, Hepatocellular carcinoma.
- TrialLEAP-012
Shares TACE + immunotherapy/anti-VEGF, Transarterial chemoembolisation (TACE), Lenvatinib, Hepatocellular carcinoma.
- TrialHIMALAYA
Shares Tremelimumab, Durvalumab, Hepatocellular carcinoma.
- TrialCASPIAN
Shares Tremelimumab, Durvalumab.
- TrialLEAP-002
Shares Lenvatinib, Hepatocellular carcinoma.
- CompanyBoston Scientific
Shares Transarterial chemoembolisation (TACE), Hepatocellular carcinoma.
- TrialREFLECT
Shares Lenvatinib, Hepatocellular carcinoma.
- PairingPD-1 blockade + chemotherapy in PD-L1-low NSCLC
Shares Tremelimumab, Durvalumab.